Eligard Information Center
Not an actual patient.
uncover the eligard® standard of care
divider line

WELCOME TO MORE

Proven efficacy1

ELIGARD delivers profound, reliable, and consistent T suppression to low levels
VIEW DATA

Customizable dosing1,2

Subcutaneous administration, with more injection site options and 4 dosing selections to meet individual patient needs
DISCOVER DOSING OPTIONS

Extended control1,3

Unique in situ polymeric gel technology enables sustained efficacy through the dosing period
EXPLORE DELIVERY SYSTEM

Unmatched access
& support

Responsible pricing, extensive services, and a comprehensive variety of resources ensure care continuity for both you and your patients

FIND MORE SUPPORT
ELIGARD can be left at room temperature for up to 8 weeks (56 days) prior to mixing and administration, offering more flexibility for your practice1
T, testosterone.
References: 1. ELIGARD (leuprolide acetate). Prescribing Information. Tolmar, Inc. 2024. 2. Prettyman J, Engel L, Boldt-Houle DM, Atkinson S, Wilt W. Personalizing treatment in the delivery of care by nurses to patients with prostate cancer. Urologic Nursing. 2019;39(2):83-99. 3. Sartor O. Eligard®: a new form of treatment for prostate cancer. Eur Urol Open Sci. 2006;5(18):P905-P910.
Tap for safety information

IMPORTANT SAFETY INFORMATION

ELIGARD® (leuprolide acetate) for injectable suspension is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer.
ELIGARD is contraindicated in patients with hypersensitivity to GnRH, GnRH agonists, or any of the components of ELIGARD. Anaphylactic reactions to synthetic GnRH or GnRH agonists have been reported in the literature. Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression. Monitor patients at risk closely and manage as appropriate.
Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose level and manage according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death and stroke has also been reported with use of GnRH agonists in men. Monitor for cardiovascular disease and manage according to current clinical practice. Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits. Convulsions have been observed in patients taking leuprolide acetate with or without a history of predisposing factors. Manage convulsions according to current clinical practice. Severe cutaneous adverse reactions (SCARs), including Steve-Johnson syndrome/toxic epidermal necrolysis, and erythema multiforme, occurred in patients receiving ELIGARD. Monitor for and advise patients of the signs and symptoms of SCARs. May cause fetal harm.
ELIGARD may impair fertility in males of reproductive potential.
The most common injection site adverse events are transient burning and stinging, pain, bruising, and erythema. The most common systemic adverse events include mild to severe hot flashes/sweats, malaise and fatigue, weakness, myalgia, dizziness, clamminess, testicular atrophy, and gynecomastia. As with other GnRH agonists, other adverse reactions, including decreased bone density and rare cases of pituitary apoplexy have been reported.

Please see full Prescribing Information for ELIGARD.

You are now leaving
ELIGARDhcp.COM

Are you sure you want to leave? 

continue to site
cancel
Skip to content